854778-42-0

Basic information

• Product Name: 4-bromo-1-(bromomethyl)-2-methoxybenzene
• Synonyms: 4-bromo-1-(bromomethyl)-2-methoxybenzene;4-Bromo-2-methoxybenzyl bromide;Benzene, 4-bromo-1-(bromomethyl)-2-methoxy-
• CAS NO: 854778-42-0
• Molecular Formula: C8H8Br2O
• Molecular Weight: 279.95652
• Mol File: 854778-42-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-bromo-1-(bromomethyl)-2-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-1-(bromomethyl)-2-methoxybenzene(854778-42-0)
• EPA Substance Registry System: 4-bromo-1-(bromomethyl)-2-methoxybenzene(854778-42-0)

Safety Data

• Hazardous Substances Data: 854778-42-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-1-(bromomethyl)-2-methoxybenzene is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-1-(bromomethyl)-2-methoxybenzene serves as an essential building block for the creation of novel agrochemicals. Its reactivity and structural features contribute to the design of effective pesticides and other agricultural chemicals.
Used in Organic Synthesis Research:
4-bromo-1-(bromomethyl)-2-methoxybenzene is utilized as a versatile compound in organic synthesis research. Its unique chemical properties enable the exploration of new reaction pathways and the synthesis of complex organic molecules for various applications.
Used in Chemical Intermediates Production:
As a chemical intermediate, 4-bromo-1-(bromomethyl)-2-methoxybenzene plays a crucial role in the production of other organic compounds. Its presence in the synthesis process allows for the creation of a wide range of specialty chemicals used across different industries.

InChI:InChI=1S/C8H8Br2O/c1-11-8-4-7(10)3-2-6(8)5-9/h2-4H,5H2,1H3

Upstream product

• 67868-73-9 5-bromo-2-methylphenol methyl ether 
• 36138-76-8 5-bromo-2-methylphenol 
• 139102-34-4 methyl 4-bromo-2-methoxybenzoate 
• 17102-63-5 (4-bromo-2-methoxyphenyl)methanol 
• 50-00-0 formaldehyd 
• 2398-37-0 3-methoxyphenyl bromide 

Relevant articles and documents

BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS

The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

MLKL INHIBITORS

Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS

The invention provides compounds of formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leuke

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

PHENOL COMPOUNDS ALS TOLL -LIKE RECEPTOR 7 AGONISTS

The invention concerns compounds of Formula (I): wherein R1, R2, R3 and Q are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful

PYRIMIDINE DERIVATIVES AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) and or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in the manufacture of a medicament for teating cardiovascular diseases, and processes for their preparation.

THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, CF3 and OCF3; -Y- represents formula (IA) R3 represents hydrogen, fluoro, chloro or C1-4alkyl; R4a and R4b each independently represent hydrogen, C1-4alkyl, C1-4alkoxy, CF3 or halo; and R5 represents a group Z-X; wherein Z is absent or represents (CH2)2 or O; and X represents formula (IB) wherein: J and L both represent CH, or one of J and L represents CH and the other represents N; when both J and L represent CH, R6 represents hydrogen, halo, CF3, C1-4alkyl or C1-4alkoxy in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, OCF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; or when one of J or L represents N, R6 represents hydrogen or halo in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; and R8 and R9 are independently selected from hydrogen and C1-4alkyl; or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in medicine, and processes for their preparation.

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

Total synthesis of (S)-equol

The first enantioselective total synthesis of (S)-equol is reported. The described route relies on an Evans alkylation to form the stereocenter and an intramolecular Buchwald etherification to generate the chroman ring. Key features of this method include its brevity, its scalability, and the low cost of starting materials.